UCBCompany Review & Valuation

Euronext Brussels
Latest Price
Market Capitalization

About UCB SA

UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. Its core products include Cimzia for rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritShow more is, ankylosing spondylitis, and Crohn's disease; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. The company also offers Zyrtec and Xyzal for allergy. Its product pipeline includes Evenity for the treatment of osteoporosis; bimekizumab for psoriasis, psoriatic arthritis, and ankylosing spondylitis diseases; dapirolizumab pegol for systemic lupus erythematosus; padsevonil for highly drug resistant epilepsy; seletalisib for Sjögren's syndrome; rozanolixizumab for immune thrombocytopenia; UCB4144/VR942 for asthma; UCB6673, UCB7858, and UCB0159 for the treatment of neurology; and UCB3491 and UCB0599 for bone treatment. UCB SA was founded in 1928 and is based in Brussels, Belgium. Show less

HQ Location
Brussels, Belgium

Stock Price

Price data not available for UCB.


Please login or create a free account to view the contents of this section.

Similar Companies

back to top